Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Moore

Showing results (21-30 of 354) with videos related to

Pageof 36
Sort By:
BMC Psychiatry|May 29, 2009
The self-reported Montgomery-Asberg Depression Rating Scale is a useful evaluative tool in Major Depressive DisorderBruno Fantino, Nicholas Moore
BMJ (Clinical Research Ed.)|April 14, 2010
Improving pharmacovigilance in EuropeNicholas Moore, Bernard Bégaud
Emergency Medicine Journal : EMJ|September 28, 2023
Evaluation of a Community Emergency Medicine acute oncology pathway using 28-day follow-upJamie Scott, Nicholas Moore
European Journal of Hospital Pharmacy : Science and Practice|June 4, 2019
Paracetamol and pain: the kiloton problemR Andrew Moore, Nicholas Moore
Postgraduate Medicine|February 9, 2018
Gastrointestinal safety and tolerability of oral non-aspirin over-the-counter analgesicsNicholas Moore, James M Scheiman
Therapie|August 20, 2011
How to improve the clinical development paradigm and its division into phases I, II and IIIMarion Bamberger, Nicholas Moore, Philippe Lechat, et al.
Handbook of Experimental Pharmacology|November 27, 2019
PharmacoepidemiologyNicholas Moore, Patrick Blin, Cécile Droz
International Clinical Psychopharmacology|April 7, 2005
Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorderNicholas Moore, Hélène Verdoux, Bruno Fantino
Pharmacoepidemiology and Drug Safety|December 4, 2012
Exploring the potential prognostic effect of various country-specific health service data on all-cause mortality using data from a large prospective study in schizophreniaAurélia Mittoux, Per Tanghøj, Nicholas Moore
Therapie|July 10, 2016
[Not Available]Marion Bamberger, Nicholas Moore, Philippe Lechat, et al.
Pageof 36

Showing results (21-30 of 354) with videos related to

Sort By:
Pageof 36
BMC Psychiatry|May 29, 2009
The self-reported Montgomery-Asberg Depression Rating Scale is a useful evaluative tool in Major Depressive DisorderBruno Fantino, Nicholas Moore
BMJ (Clinical Research Ed.)|April 14, 2010
Improving pharmacovigilance in EuropeNicholas Moore, Bernard Bégaud
Emergency Medicine Journal : EMJ|September 28, 2023
Evaluation of a Community Emergency Medicine acute oncology pathway using 28-day follow-upJamie Scott, Nicholas Moore
European Journal of Hospital Pharmacy : Science and Practice|June 4, 2019
Paracetamol and pain: the kiloton problemR Andrew Moore, Nicholas Moore
Postgraduate Medicine|February 9, 2018
Gastrointestinal safety and tolerability of oral non-aspirin over-the-counter analgesicsNicholas Moore, James M Scheiman
Therapie|August 20, 2011
How to improve the clinical development paradigm and its division into phases I, II and IIIMarion Bamberger, Nicholas Moore, Philippe Lechat, et al.
Handbook of Experimental Pharmacology|November 27, 2019
PharmacoepidemiologyNicholas Moore, Patrick Blin, Cécile Droz
International Clinical Psychopharmacology|April 7, 2005
Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorderNicholas Moore, Hélène Verdoux, Bruno Fantino
Pharmacoepidemiology and Drug Safety|December 4, 2012
Exploring the potential prognostic effect of various country-specific health service data on all-cause mortality using data from a large prospective study in schizophreniaAurélia Mittoux, Per Tanghøj, Nicholas Moore
Therapie|July 10, 2016
[Not Available]Marion Bamberger, Nicholas Moore, Philippe Lechat, et al.
Pageof 36